FORWARD I (GOG 3011): A Phase III Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate, Versus Chemotherapy in Patients with Platinum-resistant Ovarian Cancer
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.